Ascendis Pharma A/S - ASND Stock Forecast, Price & News

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ASND shares.
View ASND analyst ratings or view top-rated stocks.

10 Wall Street analysts have issued 1-year price objectives for Ascendis Pharma A/S's shares. Their ASND share price forecasts range from $130.00 to $182.00. On average, they anticipate the company's share price to reach $160.50 in the next year. This suggests a possible upside of 54.9% from the stock's current price.
View analysts price targets for ASND or view top-rated stocks among Wall Street analysts.

Ascendis Pharma A/S's stock was trading at $122.13 at the start of the year. Since then, ASND shares have decreased by 15.2% and is now trading at $103.60.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our ASND earnings forecast.

Ascendis Pharma A/S (NASDAQ:ASND) posted its earnings results on Thursday, February, 16th. The biotechnology company reported ($3.78) earnings per share for the quarter, missing the consensus estimate of ($2.50) by $1.28. The biotechnology company earned $23.38 million during the quarter, compared to analysts' expectations of $20.31 million. Ascendis Pharma A/S had a negative net margin of 1,149.60% and a negative trailing twelve-month return on equity of 114.11%.

ETFs with the largest weight of Ascendis Pharma A/S (NASDAQ:ASND) stock in their portfolio include Harbor Health Care ETF (MEDI), Putnam BioRevolution ETF (SYNB), Virtus LifeSci Biotech Products ETF (BBP), Global X Guru Index ETF (GURU), American CenturyFocused Dynamic Growth ETF (FDG), Harbor Disruptive Innovation ETF (INNO), First Trust NASDAQ BuyWrite Income ETF (FTQI) and Putnam Sustainable Future ETF (PFUT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD), Incyte (INCY), Exelixis (EXEL), GW Pharmaceuticals (GWPH) and NVIDIA (NVDA).

(ASND) raised $85 million in an initial public offering on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager.

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

Ascendis Pharma A/S's stock is owned by many different retail and institutional investors. Top institutional investors include RA Capital Management L.P. (12.20%), Artisan Partners Limited Partnership (12.14%), Price T Rowe Associates Inc. MD (6.51%), Avoro Capital Advisors LLC (5.44%), T. Rowe Price Investment Management Inc. (4.96%) and Franklin Resources Inc. (2.42%).

Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ASND stock can currently be purchased for approximately $103.60.

Ascendis Pharma A/S (NASDAQ:ASND) has a market capitalization of $5.92 billion and generates $53.93 million in revenue each year. The biotechnology company earns $-614,450,000.00 in net income (profit) each year or ($10.85) on an earnings per share basis.

The company employs 639 workers across the globe.

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The official website for the company is www.ascendispharma.com. The biotechnology company can be reached via phone at (457) 022-2244, via email at ir@ascendispharma.com, or via fax at 45-3694-4010.